Brand Industry Insists COVID-19 Relaxations Must Be Temporary
Post-Coronavirus Warnings On IP And Manufacturing From EU Pharma Industry
Executive Summary
Speakers at a recent COVID-19 webinar discussed a number of issues related to the pandemic, including intellectual property protections, matching supply with demand, and what to do about excess manufacturing capacity once the crisis is over.
You may also be interested in...
EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.